SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for SI-BONE, (SIBN) — Nov 21, 2019

SI-BONE, Inc.
Date: Nov. 21, 2019 · CIK: 0001459839 · Accession: 0000000000-19-015718

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-234679

Date
November 20, 2019
Author
Jeffrey W. Dunn
Form
UPLOAD
Company
SI-BONE, Inc.

Letter

November 20, 2019 Jeffrey W. Dunn President, Chief Executive Officer and Chairman SI-BONE, Inc. 471 El Camino Real, Suite 101 Santa Clara, CA 95050 Re:SI-BONE, Inc. Registration Statement on Form S-3 Filed November 13, 2019 File No. 333-234679 Dear Mr. Dunn: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Brett White, Esq.

Show Raw Text
November 20, 2019
Jeffrey W. Dunn
President, Chief Executive Officer and Chairman
SI-BONE, Inc.
471 El Camino Real, Suite 101
Santa Clara, CA 95050
Re:SI-BONE, Inc.
Registration Statement on Form S-3
Filed November 13, 2019
File No. 333-234679
Dear Mr. Dunn:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jeffrey Gabor at 202-551-2544 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Brett White, Esq.